1,https://www.reuters.com/article/us-laboratory-corp-jana-partners/jana-partners-nominates-directors-at-labcorp-including-crawford-idUSKBN2AN2AF,2021-02-23T20:30:17Z,"Jana Partners nominates directors at Labcorp, including Crawford","BOSTON (Reuters) - Activist investment firm Jana Partners has nominated directors to the board of life sciences company Laboratory Corp of America Holdings, including Edwin “Mac” Crawford, who has a reputation for turning around struggling companies, sources familiar with the matter said on Tuesday.","Jana Partners bought 811,661 shares in Labcorp late last year. News that it has engaged with the company and nominated directors sent the company’s share price higher on Tuesday.",The stock climbed as much as 3% but then lost some ground to trade at $246.63 in early afternoon.,Jana declined to comment.,"Crawford, a former chairman of CVS Caremark, has teamed up with Jana Partners in the past and took a board seat at Team Health Holdings along with a partner from Jana in 2016.",Bloomberg first reported that Jana had nominated directors at Labcorp.,The company did not immediately respond to requests for comment.
2,https://www.reuters.com/article/us-hedgfund-jana-holdings/activist-jana-overhauls-portfolio-takes-stake-in-labcorp-in-fourth-quarter-filing-idUSKBN2AG2NP,2021-02-16T23:15:41Z,"Activist Jana overhauls portfolio, takes stake in Labcorp in fourth quarter - filing","BOSTON (Reuters) - Activist investment firm Jana Partners made big portfolio changes at the end of 2020, buying a stake in life sciences company Laboratory Corp of America Holdings and exiting long-owned stocks including Callaway Golf Co and HD Supply Holdings which was sold to Home Depot.","Jana Partners bought 811,661 shares in Laboratory Corp of America Holdings, known as Labcorp, making it one of the firm’s five largest investments, according to a regulatory filing made on Tuesday.","Jana, founded by Barry Rosenstein, has a history of pushing for change in the healthcare space and also owns a stake in Encompass Health Corp. A spokesman for the firm declined to comment on how it may proceed with its Labcorp investment.","Jana also added new stakes in materials company W. R. Grace & Co. and communications company Tegna, which last year beat back an activist investor’s efforts to elect directors to the regional TV station operator’s board.",The filing shows Jana also increased its holdings in consumer staples company TreeHouse Foods Inc during the fourth quarter of 2020.,Last week Jana nominated three directors to TreeHouse’s board and is pushing management to consider a possible sale.,"Jana has experience in pushing for consolidation in the consumer space, having lobbied for the sale of Pinnacle Foods and for changes at Whole Foods Market Inc. before it was sold to Amazon.com Inc."
3,https://www.reuters.com/article/health-coronavirus-laboratory-corp/labcorp-launches-test-to-measure-covid-19-antibodies-in-clinical-trials-idUSL4N2HA2Y6,2020-10-19T11:23:43Z,LabCorp launches test to measure COVID-19 antibodies in clinical trials,"Oct 19 (Reuters) - LabCorp said on Monday it has launched a test that can measure antibodies a person has produced against the novel coronavirus, to determine the effectiveness of vaccines and drugs against the respiratory illness caused by the virus.","The test, Cov2Quant, is available for use only in clinical trials and research, the company said.","Developing a safe and effective vaccine against the coronavirus is deemed crucial to bring the pandemic under control and several drugmakers, including Johnson & Johnson , Moderna Inc and Pfizer Inc have late-stage clinical studies underway to assess their vaccine candidates.","The level of antibodies, or disease-fighting proteins, is an important indicator of the strength of a person’s immune response, which can help determine the effectiveness of vaccines and therapies in clinical studies, LabCorp said.","The company said it has performed more than 17 million molecular tests since March and is now able to process 210,000 tests per day. LabCorp also said it has performed 3 million COVID-19 antibody tests so far, with the capacity to perform 300,000 per day. (Reporting by Manojna Maddipatla in Bengaluru; Editing by Shounak Dasgupta)"
4,https://www.reuters.com/article/us-laboratory-corp-results/labcorp-says-needs-to-run-testing-below-full-capacity-for-faster-results-idUSKCN24T1HE,2020-07-28T16:34:24Z,LabCorp says needs to run testing below full capacity for faster results,"(Reuters) - Laboratory Corporation of America Holdings LH.N said on Tuesday it has the capacity to run about 180,000 molecular tests a day and was delivering results in two-three days, but to maintain the speed it will have to perform below full capacity.","Adequate diagnostic testing and faster processing are crucial for the United States, which leads the world in COVID-19 deaths. It has reported nearly 148,500 deaths so far and more than 4 million cases of infection.","Last week, LabCorp received the U.S. authorization for emergency use of its pooled testing, a method that tests several patient samples at once, which it said will help it achieve its targets for expanded testing capacity.","Pool testing is particularly helpful in areas with low prevalence, such as back-to-school or back-to-work settings, Chief Executive Officer Adam Schechter said on a post-earnings conference call.","LabCorp, which offers antibody, neutralizing antibody and molecular tests for the coronavirus, has been struggling to expand capacity for its COVID-19 tests, like peer Quest Diagnostics Inc DGX.N that aims to run 150,000 tests per day by next month.","Quest’s current turnaround time for COVID-19 tests is about a week, which it expects to cut by more than half by September, compared to LabCorp’s average of two-three days.","“We’re going to continue to ensure that we do as many tests as we can, but we want to manage the turnaround time as best we can as well,” Schechter said. LabCorp said demand for its non-COVID-19 tests continues to be below historical levels, but has been recovering from its trough in April.","Excluding items and CARES Act stimulus, LabCorp reported a profit of $2.57 per share for the quarter ended June 30, exceeding analysts’ estimates of $1 per share, according to Refinitiv IBES data.",The company’s shares were down 1% at $199.07.
5,https://www.reuters.com/article/laboratory-corp-conference/labcorp-says-need-to-run-testing-below-full-capacity-to-maintain-shorter-turnaround-time-idUSL3N2EZ3IV,2020-07-28T14:21:38Z,LabCorp says need to run testing below full capacity to maintain shorter turnaround time,July 28 (Reuters) - Laboratory Corporation of America Holdings Chief Executive Officer Adam Schechter said on Tuesday COVID-19 testing should not be run at full capacity to ensure shorter turnaround time for results.,"The company, which currently has the capacity to run about 180,000 molecular tests per day, said it has reduced the turnaround time for results to two-three days on average, which is even faster for hospital inpatients."
6,https://www.reuters.com/article/brief-labcorp-says-launched-labcorp-at-h/brief-labcorp-says-launched-labcorp-at-home-covid-19-test-collection-service-idUSFWN2EE07T,2020-07-07T12:23:32Z,BRIEF-Labcorp Says Launched Labcorp At Home COVID-19 Test Collection Service,July 7 (Reuters) - Laboratory Corporation of America Holdings:,* LABCORP - LAUNCHED LABCORP AT HOME COVID-19 TEST COLLECTION SERVICE Source text for Eikon: Further company coverage:
7,https://www.reuters.com/article/brief-humana-to-offer-labcorp-at-home-co/brief-humana-to-offer-labcorp-at-home-covid-19-test-collection-collaborate-with-walmart-and-quest-diagnostics-to-offer-drive-thru-testing-for-humana-members-idUSFWN2E70S0,2020-06-30T12:45:27Z,"BRIEF-Humana To Offer Labcorp At-Home COVID-19 Test Collection, Collaborate With Walmart And Quest Diagnostics To Offer Drive-Thru Testing For Humana Members",June 30 (Reuters) - Humana Inc:,* HUMANA TO OFFER LABCORP AT-HOME COVID-19 TEST COLLECTION AND COLLABORATE WITH WALMART AND QUEST DIAGNOSTICS TO OFFER DRIVE-THRU TESTING FOR HUMANA MEMBERS Source text for Eikon: Further company coverage:
8,https://www.reuters.com/article/brief-labcorp-introduces-xcellerate-covi/brief-labcorp-introduces-xcellerate-covid-19-clinical-study-solution-idUSFWN2E60F4,2020-06-29T11:49:21Z,BRIEF-Labcorp Introduces Xcellerate Covid-19 Clinical Study Solution,June 29 (Reuters) - Laboratory Corporation of America Holdings:,* LABCORP INTRODUCES XCELLERATE® COVID-19 CLINICAL STUDY SOLUTION Source text for Eikon: Further company coverage:
9,https://www.reuters.com/article/us-health-coronavirus-laboratory-corp/labcorp-launches-new-neutralizing-antibody-test-for-covid-19-idUSKBN23W1QK,2020-06-25T11:37:16Z,LabCorp launches new neutralizing antibody test for COVID-19,(Reuters) - LabCorp said on Thursday it has launched a new test that could assess the capacity of antibodies in patient plasma to inhibit the novel coronavirus.,"Information from the test about the virus-fighting ability of antibodies could be used in the development of COVID-19 vaccines, the company said.","The test, called the neutralizing antibody test, would be available to biopharmaceutical companies, hospitals, blood banks and other blood plasma-screening facilities.","Neutralizing antibodies are associated with protective immunity against re-infection for many infectious pathogens, according to the Mayo Clinic.","The test could be used in screening serum collected from recovered COVID-19 patients for preventive and therapeutic use, the company said.","The company made its COVID-19 tests available at workplaces last month and it also provides lab tests and antibody blood tests that can tell whether a person has ever been infected, as well as kits that allow people to mail in their own nasal swab samples collected at home."
10,https://www.reuters.com/article/healthcoronavirus-laboratory-corp/labcorp-launches-new-antibody-test-for-covid-19-idUSL4N2E21XJ,2020-06-25T11:07:32Z,LabCorp launches new antibody test for COVID-19,June 25 (Reuters) - LabCorp said on Thursday it has launched a new test that could assess the capacity of antibodies in patient plasma to inhibit the novel coronavirus.,"Information from the test about the disease-fighting ability of antibodies could be used in the development of COVID-19 vaccines, the company said. (Reporting by Manojna Maddipatla in Bengaluru; Editing by Aditya Soni)"
11,https://www.reuters.com/article/brief-labcorp-launches-new-neutralizing/brief-labcorp-launches-new-neutralizing-antibody-test-idUSFWN2E20A8,2020-06-25T10:58:44Z,BRIEF-LabCorp Launches New Neutralizing Antibody Test,June 25 (Reuters) - Laboratory Corporation of America Holdings:,* LABCORP - LAUNCH OF NEW TEST THAT CAN BE USED TO ASSESS CAPACITY OF ANTIBODIES IN PATIENT PLASMA TO INHIBIT SARS-COV-2 VIRUS Source text for Eikon: Further company coverage:
12,https://www.reuters.com/article/brief-labcorp-launches-new-covid-19-tria/brief-labcorp-launches-new-covid-19-trial-site-to-connect-patients-with-u-s-research-trials-idUSFWN2DE0FF,2020-06-01T11:05:24Z,BRIEF-Labcorp Launches New Covid-19 Trial Site To Connect Patients With U.S. Research Trials,June 1 (Reuters) - Laboratory Corporation of America Holdings:,* LABCORP LAUNCHES NEW COVID-19 CLINICAL TRIAL SITE TO CONNECT PATIENTS WITH U.S. RESEARCH TRIALS,"* LABCORP - COVANCE, ITS DRUG DEVELOPMENT BUSINESS, HAS CREATED COVID-19 CLINICAL TRIAL CONNECT IN U.S. Source text for Eikon: Further company coverage:"
13,https://www.reuters.com/article/health-coronavirus-labcorp/labcorp-ties-up-with-software-provider-to-expand-virtual-clinical-trials-idUSL1N2DA12Z,2020-05-28T14:34:40Z,LabCorp ties up with software provider to expand virtual clinical trials,"Medable’s modular software platform will help patients registered with LabCorp’s drug development unit Covance to participate in decentralized clinical trials and facilitate remote data collection and engagement between patients, sites and clinical investigators.","In recent months, clinical trial service providers have reported a spike in demand for virtual trials as pharmaceutical companies try to prevent the coronavirus outbreak from derailing their drug rollouts.","Covance, which has been offering decentralized clinical trials, will expand its technology ecosytem to accelerate timelines for clinical development, the company said.",Medable CEO Michelle Longmire said this decentralized trial ecosystem will help patients receive effective therapies at a faster pace.
14,https://www.reuters.com/article/us-health-coronavirus-labcorp/labcorp-ties-up-with-software-provider-to-expand-virtual-clinical-trials-idUSKBN2341RU,2020-05-28T12:33:56Z,LabCorp ties up with software provider to expand virtual clinical trials,"(Reuters) - Laboratory Corporation of America Holdings (LabCorp) said on Thursday it was partnering with software provider Medable to speed up the adoption of virtual clinical trials, as many participants are dropping out of ongoing studies due to the COVID-19 pandemic.","Medable’s modular software platform will help patients registered with LabCorp’s drug development unit Covance to participate in decentralized clinical trials and facilitate remote data collection and engagement between patients, sites and clinical investigators.","In recent months, clinical trial service providers have reported a spike in demand for virtual trials as pharmaceutical companies try to prevent the coronavirus outbreak from derailing their drug rollouts.","Covance, which has been offering decentralized clinical trials, will expand its technology ecosytem to accelerate timelines for clinical development, the company said.",Medable CEO Michelle Longmire said this decentralized trial ecosystem will help patients receive effective therapies at a faster pace.
15,https://www.reuters.com/article/health-coronavirus-labcorp/labcorp-to-work-with-software-provider-for-virtual-clinical-trials-idUSL4N2DA2TE,2020-05-28T11:26:36Z,LabCorp to work with software provider for virtual clinical trials,May 28 (Reuters) - Laboratory Corporation of America Holdings (LabCorp) said on Thursday it was collaborating with software provider Medable to accelerate adoption of virtual clinical trials.,"Medable’s modular software platform will help patients registered with LabCorp to participate in decentralized clinical trials and facilitate remote data collection and engagement between patients, sites, and clinical investigators."
16,https://www.reuters.com/article/brief-labcorp-to-adopt-decentralized-cli/brief-labcorp-to-adopt-decentralized-clinical-trials-expand-technology-ecosystem-idUSASA00RTK,2020-05-28T11:25:18Z,"BRIEF-Labcorp To Adopt Decentralized Clinical Trials, Expand Technology Ecosystem",May 28 (Reuters) - Laboratory Corporation of America Holdings:,"* LABCORP ACCELERATES ADOPTION OF DECENTRALIZED CLINICAL TRIALS, EXPANDS TECHNOLOGY ECOSYSTEM THROUGH ALLIANCE WITH MEDABLE",* LABCORP - COVANCE IS EXPANDING DECENTRALIZED TRIALS TECHNOLOGY ECOSYSTEM THROUGH ALLIANCE WITH MEDABLE,* LABCORP - COVANCE PATIENT & SITE INTERFACE WILL BE POWERED BY MEDABLE’S MODULAR SOFTWARE PLATFORM Source text for Eikon: Further company coverage:
17,https://www.reuters.com/article/us-health-coronavirus-laboratory-corp/labcorp-to-make-covid-19-testing-services-available-at-workplaces-idUSKBN22Q23S,2020-05-14T13:13:23Z,LabCorp to make COVID-19 testing services available at workplaces,"(Reuters) - Diagnostic services provider LabCorp said on Thursday it would make its COVID-19 tests available at workplaces, as employers across the United States look to bring people back to work safely.","The company said it would provide customized services for workplaces including temperature checks, COVID-19 test collection at offices, access to its at-home sample collection kit, antibody test, as well as flu vaccinations in the fall.","With millions of Americans out of work in a coronavirus-battered economy, a growing number of states are relaxing the restrictions put in place to slow the outbreak even as the number of infections continues to rise.","Public health experts have warned that rushing to relax the restrictions, without having vastly expanded testing and other precautions firmly in place would risk the resurgence of the virus.","LabCorp currently provides lab tests, antibody blood tests that can tell whether a person has ever been infected, as well as kits that allow people to mail in their own nasal swab samples, reducing risks of further transmission.","Earlier this week, the company expanded delivery of the at-home collection kits to all customers, after having limited availability to healthcare workers during the launch last month.",LabCorp said its “return to work” offerings would also include wellness services such as biometric screening.
18,https://www.reuters.com/article/brief-labcorp-launching-a-new-return-to/brief-labcorp-launching-a-new-return-to-work-service-for-employers-idUSFWN2CW0SK,2020-05-14T11:37:17Z,BRIEF-Labcorp - Launching A New Return To Work Service For Employers,Laboratory Corporation of America Holdings:,* LABCORP - LAUNCHING A NEW RETURN TO WORK SERVICE FOR EMPLOYERS,* LABCORP - LABCORP EMPLOYER SERVICES PROVIDES CUSTOMIZED RETURN TO WORK SOLUTIONS USING LABCORP’S TRAINED MEDICAL STAFF FOR EMPLOYEE CHECK-INS Source text for Eikon: Further company coverage:
19,https://www.reuters.com/article/us-health-coronavirus-laboratory-corp/labcorp-expands-availability-of-at-home-sample-collection-kit-for-covid-19-test-idUSKBN22O2EM,2020-05-12T15:50:40Z,LabCorp expands availability of at-home sample collection kit for COVID-19 test,"(Reuters) - LabCorp said on Tuesday its at-home sample collection kit for COVID-19 testing would now be available to all individuals with symptoms and possible exposure to the virus, after limiting delivery to healthcare workers during its launch last month.","The collection kit, with a list price of $119, consists of cotton swabs to collect nasal specimens, a biohazard specimen bag and a FedEx overnight shipping envelope to mail the samples to labs.","Customers can get the kit with no upfront out-of-pocket costs if they are found to be eligible after filling in a survey on the company’s website, LabCorp said.","The company said it would submit the claim to the individual’s health insurance agency, or the appropriate government program, in case the person does not have insurance.","At-home sample collection reduces the risk of transmitting the coronavirus to medical staff, but has possible shortcomings, including whether a patient can collect the sample properly and ship it safely to the lab.","The U.S. Food and Drug Administration has said it had worked with the company to ensure that data from its sample collection kit is as safe and accurate as it is at a doctor’s office, hospital or other testing sites.","LabCorp said it currently has over 200,000 at-home collection kits and was prepared to significantly expand capacity as required.","In addition to its COVID-19 lab test launched early in March, LabCorp offers an antibody blood test that can confirm whether the person has ever been infected with the virus."
20,https://www.reuters.com/article/health-coronavirus-laboratory-corp/labcorp-expands-availability-of-at-home-sample-collection-kit-for-covid-19-testing-idUSL4N2CU2X5,2020-05-12T12:26:34Z,LabCorp expands availability of at-home sample collection kit for COVID-19 testing,"May 12 (Reuters) - LabCorp said on Tuesday it has now made available its at-home sample collection kit for COVID-19 testing to all individuals with symptoms and possible exposure to the virus, after having limited delivery to healthcare workers last month.","The collection kit, launched in April with a list price of $119, comes with cotton swabs to collect nasal specimens, a biohazard specimen bag and a FedEx overnight shipping envelope to mail the samples to labs.","LabCorp said it has over 200,000 at-home collection kits and was prepared to significantly expand capacity as required.","At-home sample collection reduces the risk of transmitting the coronavirus to medical staff but has possible shortcomings, including whether a patient can collect the sample properly and ship it safely to the lab.","In addition to a COVID-19 lab test that was launched early in March, LabCorp offers an antibody blood test that can confirm whether the person has ever been infected with the virus. (Reporting by Saumya Sibi Joseph in Bengaluru; Editing by Ramakrishnan M.)"
21,https://www.reuters.com/article/brief-labcorp-significantly-expands-avai/brief-labcorp-significantly-expands-availability-of-its-covid-19-at-home-collection-test-kit-idUSFWN2CU0VF,2020-05-12T11:47:49Z,BRIEF-Labcorp Significantly Expands Availability Of Its Covid-19 At-Home Collection Test Kit,May 12 (Reuters) - Laboratory Corporation of America Holdings:,* LABCORP SIGNIFICANTLY EXPANDS AVAILABILITY OF ITS COVID-19 AT-HOME COLLECTION TEST KIT,"* LABCORP - COVID-19 AT-HOME TEST KIT NOW BEING OFFERED TO INDIVIDUALS WHO HAVE SYMPTOMS CONSISTENT WITH INFECTION, INDIVIDUALS WITHOUT SYMPTOMS",* LABCORP - TEST IS AVAILABLE THROUGH COMPANY’S PIXEL BY LABCORP ONLINE PLATFORM.,"* LABCORP - NOW HAS OVER 200,000 AT-HOME COLLECTION TEST KITS AVAILABLE AND IS PREPARED TO SIGNIFICANTLY EXPAND CAPACITY AS REQUIRED","* LABCORP - COVID-19 AT-HOME TEST KIT IS PHYSICIAN-AUTHORIZED, ENABLES INDIVIDUALS TO SELF-COLLECT NASAL SWAB SPECIMENS AT HOME Source text for Eikon: Further company coverage:"
22,https://www.reuters.com/article/brief-labcorp-says-covid-19-antibody-tes/brief-labcorp-says-covid-19-antibody-test-now-directly-available-through-labcorp-com-idUSFWN2CN10Y,2020-05-05T21:29:22Z,BRIEF-Labcorp Says Covid-19 Antibody Test Now Directly Available Through Labcorp.Com,May 5 (Reuters) - Laboratory Corporation of America Holdings :,* LABCORP - COVID-19 ANTIBODY TEST NOW DIRECTLY AVAILABLE THROUGH LABCORP.COM,* LABCORP - DOES NOT REQUIRE UPFRONT OUT-OF-POCKET COSTS FOR IGG ANTIBODY TEST Source text for Eikon: Further company coverage:
23,https://www.reuters.com/article/research-us/u-s-research-roundup-labcorp-servicenow-zebra-technologies-idUSL4N2CI32K,2020-04-30T17:53:10Z,"U.S. RESEARCH ROUNDUP- Labcorp, ServiceNow, Zebra Technologies"
24,https://www.reuters.com/article/brief-labcorp-q1-loss-per-share-327/brief-labcorp-q1-loss-per-share-3-27-idUSASA00MH6,2020-04-29T11:15:50Z,BRIEF-Labcorp Q1 Loss Per Share $3.27,April 29 (Reuters) - Laboratory Corporation of America Holdings:,* Q1 REVENUE $2.82 BILLION VERSUS REFINITIV IBES ESTIMATE OF $2.74 BILLION,* Q1 EARNINGS PER SHARE ESTIMATE $1.95 -- REFINITIV IBES DATA,* WITHDRAWS 2020 GUIDANCE AND TEMPORARILY SUSPENDS ITS SHARE REPURCHASE PROGRAM DUE TO UNPREDICTABILITY OF ONGOING COVID-19 PANDEMIC,"* IN LABCORP DIAGNOSTICS, DEMAND FOR TESTING DECLINED 50% TO 55% VERSUS COMPANY’S NORMAL DAILY LEVELS AT END OF Q1","* RECORDED RESTRUCTURING CHARGES, SPECIAL ITEMS, IMPAIRMENTS, AND AMORTIZATION, WHICH TOGETHER TOTALED $558.5 MILLION IN QUARTER","* QTRLY LABCORP DIAGNOSTICS REVENUE, ADJUSTING OUT INCREASE IN ACCOUNTS RECEIVABLE RESERVES WAS $1.70 BILLION, A DECREASE OF 1.2%","* REDUCTION IN QTRLY DEMAND IN LABCORP DIAGNOSTICS IMPACTED TESTING VOLUMES BROADLY, BUT WAS HEAVILY WEIGHTED TOWARDS ROUTINE TESTS","* QTRLY COVANCE DRUG DEVELOPMENT REVENUE, WAS $1.14 BILLION, AN INCREASE OF 6.4%","* QTRLY LOWER ORGANIC REVENUE INCLUDES ESTIMATED NEGATIVE IMPACT FROM COVID-19 OF 4.9% & LOWER MEDICARE, MEDICAID PRICING AS A RESULT OF PAMA OF 0.7%",* QTRLY VOLUME REDUCTION IN BASE BUSINESS OF LABCORP DIAGNOSTICS APPEARS TO HAVE STABILIZED,* QUARTER-END COVANCE DRUG DEVELOPMENT BACKLOG WAS $11.30 BILLION,"* AT END OF QUARTER, COMPANY’S CASH BALANCE AND TOTAL DEBT WERE $323.6 MILLION AND $6.2 BILLION, RESPECTIVELY","* EXPECTS TO OFFSET SOME VOLUME SHORTFALL IN LABCORP DIAGNOSTICS BY INCREASING CAPACITY FOR SEROLOGICAL ANTIBODY TESTS TO OVER 200,000 TESTS/DAY BY MID-MAY",* RECORDED $21.9 MILLION OF OTHER COVID-19 RELATED COSTS IN QUARTER,"* IN COVANCE DRUG DEVELOPMENT, PERFORMANCE HAS BEEN CHALLENGED BY COVID-19",* REDUCING CASH OUTFLOWS THROUGH DELAYING CERTAIN CAPITAL EXPENDITURES,"* AT END OF QUARTER, CO’S CASH BALANCE AND TOTAL DEBT WERE $323.6 MILLION AND $6.2 BILLION, RESPECTIVELY","* TAKING ACTIONS REGARDING WORKFORCE INCL. IMPLEMENTING FURLOUGHS; DELAYING HIRING; REDUCING TEMPORARY & CONTRACT WORKERS, INTERN POSITIONS, OVERTIME",* SUSPENDING DISCRETIONARY MERIT ADJUSTMENT FOR ALL EMPLOYEES,* EXPECTS TO DELIVER SOLID ADJUSTED EPS AND FREE CASH FLOW IN 2020,* TAKING ACTIONS TO UTILIZE AVAILABLE STIMULUS / CARES ACT BENEFITS Source text for Eikon: Further company coverage:
25,https://www.reuters.com/article/brief-labcorp-covid-19-antibody-tests-av/brief-labcorp-covid-19-antibody-tests-available-nationwide-with-no-upfront-out-of-pocket-costs-idUSFWN2CF1BY,2020-04-27T20:13:19Z,BRIEF-Labcorp Covid-19 Antibody Tests Available Nationwide With No Upfront Out-Of-Pocket Costs,April 27 (Reuters) - Laboratory Corporation of America Holdings:,* LABCORP COVID-19 ANTIBODY TESTS AVAILABLE NATIONWIDE WITH NO UPFRONT OUT-OF-POCKET COSTS,"* LABCORP - LOCATIONS INCLUDE NEARLY 2,000 LABCORP PATIENT SERVICE CENTERS INCLUDING MORE THAN 100 LABCORP AT WALGREENS LOCATIONS","* LABCORP - BY MID-MAY, LABCORP EXPECTS TO BE ABLE TO PERFORM 200,000 TESTS PER DAY Source text for Eikon: Further company coverage:"
26,https://www.reuters.com/article/us-health-coronavirus-laboratory-corp/labcorp-to-expand-availability-of-antibody-tests-for-covid-19-idUSKCN2241RX,2020-04-22T12:04:52Z,LabCorp to expand availability of antibody tests for COVID-19,(Reuters) - Laboratory and drug development services provider LabCorp said on Wednesday it would expand the availability of its antibody tests for the new coronavirus to more hospitals and healthcare organizations starting next week.,"The tests, earlier made available mainly to healthcare workers in late March, aim to identify individuals exposed to the virus but without any visible symptoms by detecting the presence of antibodies to the virus in blood samples.",LabCorp said it offers separate tests to identify three major classes of antibodies for the virus.,"Physicians would be able to direct asymptomatic patients to the company’s approximately 2,000 patient service centers for specimen collection for the antibody test, SARS-CoV-2 IgG, starting April 27, the company said.","While the tests are neither the sole basis for a diagnosis nor assurance of immunity, they could play a role in helping healthcare providers determine appropriate treatment for individuals suspected of having been infected with the virus, LabCorp’s Chief Medical Officer Brian Caveney said.","LabCorp said it expects to be able to perform several hundred thousand tests per week by mid-May, as more tests receive regulatory clearance for emergency use.","The antibody tests are in addition to LabCorp’s existing molecular test for COVID-19 that is already available nationwide through healthcare providers, the company said.","These antibody tests have not yet been reviewed by the FDA, but are in accordance with the public health emergency guidelines issued by the health regulator, the company said.","The company on Tuesday received the U.S. Food and Drug Administration’s clearance for at-home sample collection for its COVID-19 diagnostic kit, allowing patients to send in their nasal swab samples to the company’s labs for diagnosis."
27,https://www.reuters.com/article/brief-labcorp-broadens-availability-of-c/brief-labcorp-broadens-availability-of-covid-19-serological-antibody-tests-idUSFWN2CA0S4,2020-04-22T11:55:27Z,BRIEF-Labcorp Broadens Availability Of Covid-19 Serological Antibody Tests,April 22 (Reuters) - Laboratory Corporation of America Holdings:,"* LABCORP BROADENS AVAILABILITY OF COVID-19 SEROLOGICAL ANTIBODY TESTS TO HOSPITALS, HEALTHCARE ORGANIZATIONS AND THROUGH ITS PATIENT SERVICE CENTERS","* LABCORP - BY MID-MAY, LABCORP EXPECTS TO BE ABLE TO PERFORM SEVERAL HUNDRED THOUSAND TESTS PER WEEK","* LABCORP - HAS BUILT CAPACITY TO PERFORM OVER 50,000 SEROLOGICAL TESTS/DAY, COMPLETE THOSE TESTS WITHIN AVERAGE OF 1-3 DAYS FROM TIME SPECIMEN IS PICKED UP Source text for Eikon: Further company coverage:"
28,https://www.reuters.com/article/health-coronavirus-laboratory-corp/labcorp-to-expand-availability-of-antibody-tests-for-covid-19-idUSL3N2CA2RD,2020-04-22T11:18:43Z,LabCorp to expand availability of antibody tests for COVID-19,April 22 (Reuters) - LabCorp said on Wednesday it would expand serological testing for the new coronavirus to more hospitals and healthcare organizations.,"Physicians will be able to direct patients not showing COVID-19 symptoms to LabCorp’s approximately 2,000 patient service centers for specimen collection for the antibody tests starting April 27, the company said.","The tests, which aim to identify individuals who have been exposed to the virus by detecting the presence of antibodies to the virus, are in addition to LabCorp’s existing molecular test for COVID-19 that is already available nationwide through healthcare providers, the company said. (Reporting by Manojna Maddipatla in Bengaluru; Editing by Vinay Dwivedi)"
29,https://www.reuters.com/article/us-health-coronavirus-laboratory-corp/fda-authorizes-at-home-sample-collection-for-labcorps-covid-19-test-idUSKCN2231HQ,2020-04-21T16:13:47Z,FDA authorizes at-home sample collection for LabCorp's COVID-19 test,"(Reuters) - The U.S. Food and Drug Administration authorized at-home sample collection for LabCorp’s COVID-19 diagnostic kit, the agency said on Tuesday, allowing patients to send in their nasal swab samples to the company’s labs for diagnosis.","The company said it had 60,000 at-home kits available and would prioritize initial delivery to healthcare workers, expecting to expand availability to U.S. customers in the coming weeks.","The kit, which has a list price of $119, would be shipped to patients only if they are found to be eligible and requires filling in a survey on the company’s website, LabCorp said.","The United States has been working to increase its testing capacity as it contends with an onslaught of infections, with over 746,000 cases and more than 39,000 deaths.","However, testing in the country has been held back in part by the lack of trained professionals to run the tests and a shortage of personal protective gear to ensure the safety of the employees collecting samples.",At-home sample collection would reduce the risk of transmitting the virus to medical staff but could come with shortcomings including whether a patient can collect the sample properly and ship it safely to the lab.,"The FDA said it had worked with LabCorp to ensure that data from its sample collection kit, the first at-home test to be authorized by the agency, is as safe and accurate as it is at a doctor’s office, hospital or other testing sites.","“With this action, there is now a convenient and reliable option for patient sample collection from the comfort and safety of their home,” the FDA said in a statement.","As long as instructions to use the kit are followed, there would be no difference in quality or results from patient-collected samples and those collected by professionals, the company said.","The at-home kit comes with cotton swabs to collect nasal specimens, a biohazard specimen bag and a FedEx overnight shipping envelope to mail the samples to labs. Results can be expected within a day or two of receipt of the sample by the lab.","LabCorp had launched its lab test for COVID-19 early in March and currently conducts nearly 55,000-65,000 tests a day. (reut.rs/2RUKeIp)",Shares of the company were up 2% at $148.55 in morning trading.
30,https://www.reuters.com/article/health-coronavirus-laboratory-corp/labcorp-to-launch-at-home-coronavirus-test-among-healthcare-workers-idUSL3N2C904G,2020-04-21T11:09:53Z,LabCorp to launch at-home coronavirus test among healthcare workers,April 21 (Reuters) - LabCorp said on Tuesday its at-home coronavirus testing kits had won U.S. authorization and it would work to make the tests available to healthcare workers who may have been exposed to the virus or may be symptomatic.,The company said it expects to make the test kits available to U.S. consumers in the coming weeks. (Reporting by Saumya Sibi Joseph in Bengaluru; Editing by Aditya Soni)
31,https://www.reuters.com/article/brief-labcorp-covid-19-at-home-test-kit/brief-labcorp-covid-19-at-home-test-kit-receives-fda-emergency-use-authorization-idUSFWN2C90AD,2020-04-21T11:06:41Z,BRIEF-Labcorp Covid-19 At-Home Test Kit Receives FDA Emergency Use Authorization,April 21 (Reuters) - Laboratory Corporation of America Holdings:,* LABCORP COVID-19 AT-HOME TEST KIT RECEIVES FDA EMERGENCY USE AUTHORIZATION,* LABCORP - INTENDS TO MAKE COVID-19 SELF-COLLECTION KITS AVAILABLE TO CONSUMERS IN COMING WEEKS,* LABCORP - EUA PERMITS NASAL SWAB SPECIMENS TO BE COLLECTED AT HOME USING PIXEL BY LABCORP COVID-19 TEST HOME COLLECTION KIT,* LABCORP - COVID-19 AT-HOME TEST KIT WILL BE OFFERED THROUGH COMPANY’S PIXEL BY LABCORP PLATFORM,"* LABCORP - CO’S COVID-19 TEST HOME COLLECTION KIT AUTHORIZED BY FDA UNDER EUA ONLY FOR DETECTION OF NUCLEIC ACID FROM SARS-COV-2, NOT OTHER VIRUSES,PATHOGENS Source text for Eikon: Further company coverage:"
32,https://www.reuters.com/article/brief-labcorp-ciox-health-agree-to-colla/brief-labcorp-ciox-health-agree-to-collaborate-on-u-s-covid-19-patient-data-registry-idUSFWN2BX0RW,2020-04-09T11:53:21Z,"BRIEF-Labcorp, Ciox Health Agree To Collaborate On U.S. Covid-19 Patient Data Registry",April 9 (Reuters) - Laboratory Corporation of America Holdings:,* LABCORP - CO AND CIOX HEALTH ANNOUNCED AN AGREEMENT TO COLLABORATE ON A COMPREHENSIVE U.S.-BASED COVID-19 PATIENT DATA REGISTRY Source text for Eikon: Further company coverage:
33,https://www.reuters.com/article/brief-labcorp-developing-options-to-prio/brief-labcorp-developing-options-to-prioritize-covid-19-testing-for-inpatient-population-in-support-of-guidance-from-the-white-house-coronavirus-task-force-idUSFWN2BG12S,2020-03-23T13:45:19Z,BRIEF-Labcorp Developing Options To Prioritize Covid-19 Testing For Inpatient Population In Support Of Guidance From The White House Coronavirus Task Force,March 23 (Reuters) - Laboratory Corporation of America Holdings:,* LABCORP DEVELOPING OPTIONS TO PRIORITIZE COVID-19 TESTING FOR INPATIENT POPULATION IN SUPPORT OF GUIDANCE FROM THE WHITE HOUSE CORONAVIRUS TASK FORCE,* LABCORP - EXPLORING OPTIONS TO PRIORITIZE COVID-19 TESTING FOR HOSPITAL INPATIENT POPULATION WHO ARE BEING TREATED FOR SUSPECTED COVID-19 VIRUS,* LABCORP - NOW PERFORMING COVID-19 TESTING IN THREE OF ITS LARGEST LABS IN COUNTRY Source text for Eikon: Further company coverage:
34,https://www.reuters.com/article/brief-hologic-us-fda-issuing-emergency-u/brief-hologic-u-s-fda-issuing-emergency-use-authorizations-to-hologic-for-its-panther-fusion-sars-cov-2-assay-idUSFWN2B921W,2020-03-17T10:35:50Z,BRIEF-Hologic - U.S. FDA-Issuing Emergency Use Authorizations To Hologic For Its Panther Fusion Sars-Cov-2 Assay,March 17 (Reuters) - Hologic Inc:,* U.S. FDA-ISSUING EMERGENCY USE AUTHORIZATIONS TO HOLOGIC FOR ITS PANTHER FUSION SARS-COV-2 ASSAY,* U.S. FDA-ISSUING EMERGENCY USE AUTHORIZATIONS TO LABORATORY CORPORATION OF AMERICA (LABCORP) FOR ITS COVID-19 RT-PCR TEST Source text for Eikon: Further company coverage:
35,https://www.reuters.com/article/brief-labcorp-launches-test-for-coronavi/brief-labcorp-launches-test-for-coronavirus-disease-2019-idUSFWN2AY18X,2020-03-06T00:36:02Z,BRIEF-Labcorp Launches Test For Coronavirus Disease 2019 (Covid-19),March 5 (Reuters) - Laboratory Corporation of America Holdings:,* LABCORP LAUNCHES TEST FOR CORONAVIRUS DISEASE 2019 (COVID-19),"* LABCORP - MAKING ITS LABCORP 2019 NOVEL CORONAVIRUS (COVID-19), NAA TEST AVAILABLE TODAY",* LABCORP - COVID-19 TEST RESULTS WILL BE AVAILABLE IN 3-4 DAYS,"* LABCORP - IN ADDITION TO ITS TEST FOR COVID-19, ALSO ABLE TO PERFORM CDC 2019-NCOV REAL-TIME RT-PCR DIAGNOSTIC PANEL IF NEEDED TO MEET TESTING DEMAND",* LABCORP - FDA’S INDEPENDENT REVIEW OF VALIDATION IS PENDING FOR COVID-19 TEST,* LABCORP - PURSUING AN EUA FOR COVID-19 TEST Source text for Eikon: Further company coverage:
36,https://www.reuters.com/article/us-health-coronavirus-questdiagnostics/labcorp-makes-coronavirus-test-available-for-ordering-in-u-s-idUSKBN20S1TS,2020-03-05T22:10:14Z,LabCorp makes coronavirus test available for ordering in U.S.,"(Reuters) - Diagnostics company Laboratory Corp of America Holdings said on Thursday it will make its coronavirus test available for ordering by healthcare providers from 6 p.m. ET, as the U.S. government ramps up efforts to increase diagnostic capabilities.",The news comes as Quest Diagnostics Inc and OPKO Health Inc also said they would be able to begin testing for the virus from next week.,"The ongoing struggle to expand local testing has been criticized as an early misstep in the government’s response to the outbreak, which has killed more than 3,300 people around the globe, including 11 in the United States.","U.S. health officials said on Thursday they expect to deliver enough coronavirus tests to public laboratories this week to test about 400,000 people.","Officials expect to ship additional test kits to cover between 1.5 million and 1.7 million people by the end of next week, U.S. Health and Human Services Secretary Alex Azar told reporters.","The FDA said last week it would allow some laboratories to immediately use the tests they have developed and validated, while they await the U.S. health regulator’s emergency-use authorization, to achieve more rapid testing capacity.",Co-Diagnostics Inc said it was seeing a surge in demand for its coronavirus test kits following the FDA policy change.,"Previously, only testing kits developed by the U.S. Centers for Disease Control and Prevention, many of which were found to be faulty, could be used in public health labs.","Quest Diagnostics said its services will be provided as a laboratory developed test, pending review by the FDA under emergency-use authorization.","The company said its test service would use respiratory specimens collected in appropriate health care environments, such as hospitals.","Vice President Mike Pence said on Wednesday the U.S. Department of Health and Human Services had included coronavirus testing as an essential health benefit, which would require most health plans as well as the government Medicare and Medicaid programs to cover the tests.","Analysts at Evercore ISI expect lab tests developed by Quest and LabCorp to be priced around $45 to $50, similar to a flu test.","OPKO Health and Co-Diagnostics closed up 24.1% and 19% respectively, while LabCorp’s shares closed down 2.2%."
37,https://www.reuters.com/article/us-healthcare-coronavirus-laboratory-cor/labcorp-to-make-coronavirus-test-available-for-ordering-in-u-s-idUSKBN20S2T7,2020-03-05T21:11:12Z,LabCorp to make coronavirus test available for ordering in U.S.,(Reuters) - Diagnostics company Laboratory Corp of America Holdings said on Thursday it plans to make its test for the new coronavirus available for ordering by healthcare providers in the United States from 6 p.m. ET.,"The test detects the presence of the coronavirus and is for use in patients who meet the current guidance for testing, the company said."
38,https://www.reuters.com/article/us-health-coronavirus-usa-labs/former-fda-chief-tells-labcorp-quest-diagnostics-to-step-up-amid-coronavirus-outbreak-idUSKBN20R2AR,2020-03-04T17:32:37Z,"Former FDA chief tells Labcorp, Quest Diagnostics to ""step up"" amid coronavirus outbreak","(Reuters) - Laboratory Corp of America Holding LH.N and Quest Diagnostics Inc DGX.N should conduct tests for coronavirus in the country, former Food & Drug Administration commissioner Scott Gottlieb tweeted bit.ly/2PMXwWn on Wednesday.","Gottlieb, who is part of Pfizer Inc's PFE.N board, said high complexity labs that perform national testing have the same ability to validate tests as academic and hospital labs that are stepping up to increase testing capacity.","“LabCorp, Quest, others; need to get in the game.”",U.S. Food and Drug Administration Commissioner Stephen Hahn told Congress on Tuesday that testing kits should be available by the end of the week that would give labs the capacity to perform about 1 million coronavirus tests.,"In addition to tests distributed by the U.S. Centers for Disease Control and Prevention (CDC) to public health labs, tests are being made by commercial test maker Integrated DNA Technologies, an FDA spokeswoman told Reuters.","The FDA is working with other commercial and academic laboratories to provide even more testing capacity, spokeswoman Stephanie Caccomo said.",Labcorp and Quest Diagnostics did not immediately respond to a request for comment.,The latest data lists 108 confirmed and presumed cases and nine deaths in the United States so far from the outbreak.,"Last month, Labcorp said it had started developing its own test for the coronavirus and had engaged with U.S. health agency to make the test available to commercial labs. [nL4N2AD42U]"
39,https://www.reuters.com/article/brief-resolution-bioscience-and-labcorp/brief-resolution-bioscience-and-labcorp-will-collaborate-to-commercialize-the-resolution-ctdx-lung-liquid-biopsy-assay-idUSFWN2AO0LB,2020-02-24T13:08:55Z,BRIEF-Resolution Bioscience And Labcorp Will Collaborate To Commercialize The Resolution ctDx Lung™ Liquid Biopsy Assay,Feb 24 (Reuters) - Laboratory Corporation of America Holdings:,* RESOLUTION BIOSCIENCE AND LABCORP WILL COLLABORATE TO COMMERCIALIZE THE RESOLUTION CTDX LUNG™ LIQUID BIOPSY ASSAY Source text for Eikon: Further company coverage:
40,https://www.reuters.com/article/us-china-health-laboratory-corp/labcorp-begins-work-on-developing-coronavirus-test-idUSKBN207208,2020-02-13T14:49:20Z,LabCorp begins work on developing coronavirus test,"(Reuters) - LabCorp said on Thursday it has begun work on developing its own test for the coronavirus that has killed over 1,300 in China.","Since late January, the U.S. Centers for Disease Control and Prevention has rushed to distribute the agency’s testing kits to allow states to do their own testing rather than ship all samples to CDC headquarters in Atlanta.","The laboratory service provider said it had immediately engaged with the CDC on its test being available to commercial labs and is preparing to support the global response, if necessary.","LabCorp also said it had seen minimal impact to its business due to the outbreak, particularly in China, where the usually week-long Lunar New Year holiday was extended by 10 days in much of the country amid mounting alarm over the epidemic.","“We’ll have to watch quarter-by-quarter if there’s any minor impact. But over the year period of time, we think that we’ll be fine based on what we know today,” Chief Executive Officer Adam Schechter said on a conference call with analysts."
41,https://www.reuters.com/article/brief-labcorp-announces-q4-earnings-per/brief-labcorp-announces-q4-earnings-per-share-2-32-idUSASA00D9X,2020-02-13T12:01:46Z,BRIEF-Labcorp Announces Q4 Earnings Per Share $2.32,Feb 13 (Reuters) - Laboratory Corporation of America Holdings:,* LABCORP ANNOUNCES 2019 FOURTH QUARTER AND FULL YEAR RESULTS AND PROVIDES 2020 GUIDANCE,* Q4 EARNINGS PER SHARE ESTIMATE $2.80 -- REFINITIV IBES DATA,* LABCORP SEES 2020 FREE CASH FLOW OF $950 MILLION TO $1.05 BILLION,"* LABCORP - LABCORP DIAGNOSTICS REVENUE FOR QUARTER WAS $1.76 BILLION, AN INCREASE OF 3.7% OVER $1.69 BILLION IN Q4 OF 2018","* LABCORP - COVANCE DRUG DEVELOPMENT REVENUE FOR QUARTER WAS $1.20 BILLION, AN INCREASE OF 9.3% OVER $1.10 BILLION IN Q4 OF 2018",* LABCORP SEES 2020 REVENUE GROWTH IN LABCORP DIAGNOSTICS OF 0.5% TO 2.5%,* LABCORP SEES 2020 REVENUE GROWTH IN COVANCE DRUG DEVELOPMENT OF 7.0% TO 9.5%,* FY2020 EARNINGS PER SHARE VIEW $11.98 -- REFINITIV IBES DATA Source text for Eikon: Further company coverage:
42,https://www.reuters.com/article/brief-labcorp-and-qiagen-announce-new-co/brief-labcorp-and-qiagen-announce-new-companion-diagnostic-for-metastatic-breast-cancer-idUSFWN23E07G,2019-06-07T20:25:43Z,BRIEF-Labcorp And Qiagen Announce New Companion Diagnostic For Metastatic Breast Cancer,June 7 (Reuters) - Laboratory Corporation of America Holdings:,* LABCORP AND QIAGEN ANNOUNCE NEW THERASCREEN PIK3CA MUTATION ANALYSIS COMPANION DIAGNOSTIC FOR METASTATIC BREAST CANCER,* LABCORP - THERASCREEN COMPANION DIAGNOSTIC IDENTIFIES WHETHER A PATIENT HAS THE SPECIFIC GENE MUTATION THAT IS A PREREQUISITE FOR TREATMENT WITH PIQRAY Source text for Eikon: Further company coverage:
43,https://www.reuters.com/article/health-labcorp/pennsylvania-insurer-labcorp-defeat-lawsuit-by-rival-lab-idUSL2N1WQ25X,2018-10-10T21:27:42Z,"Pennsylvania insurer, LabCorp defeat lawsuit by rival lab",A federal judge has dismissed a lawsuit by a lab-testing company alleging that a health insurer and Laboratory Corporation of America Holdings worked to eliminate competition for the testing of sexually transmitted diseases in parts of Pennsylvania.,U.S. District Judge Gerald Pappert in Philadelphia on Tuesday ruled Medical Diagnostic Laboratories (MDL) lacked evidence to support its claims that Independence Blue Cross and LabCorp interfered with its relationships with healthcare providers.,"To read the full story on WestlawNext Practitioner Insights, click here: bit.ly/2Ee9ftK"
44,https://www.reuters.com/article/brief-eurofins-scientific-acquires-labco/brief-eurofins-scientific-acquires-labcorps-food-testing-and-consulting-business-idUSFWN1S701H,2018-04-30T05:50:35Z,BRIEF-Eurofins Scientific Acquires LabCorp's Food Testing And Consulting Business,April 30 (Reuters) - EUROFINS SCIENTIFIC SE:,* ACQUISITION OF LABCORP’S FOOD TESTING AND CONSULTING BUSINESS,* AGREED ACQUISITION PRICE IS US$670M ON A CASH FREE DEBT FREE BASIS Source text for Eikon: Further company coverage: (Gdynia Newsroom)
45,https://www.reuters.com/article/us-laboratory-corp-results/labcorps-covance-business-powers-quarterly-profit-beat-shares-rise-idUSKBN1HW1IT,2018-04-25T16:39:30Z,LabCorp's Covance business powers quarterly profit beat; shares rise,"(Reuters) - Laboratory Corp of America Holdings LH.N posted a quarterly profit on Wednesday that beat analysts' estimates, helped by higher demand at the unit performing clinical trials for drugmakers, and prompting the company to raise its full-year revenue target.","The company’s Covance unit, which has been steadily improving, hit $1 billion in sales for the first time, benefiting from the acquisition of privately held CRO Chiltern International.","Covance sales rose 39.3 percent to $1.08 billion, better than consensus estimates of $1.02 billion by Evercore ISI.",LabCorp has been acquiring contract research organizations as drugmakers try to cut costs by outsourcing clinical trials.,"“It is reassuring to see Covance pivot to growth after 1H17 declines, and that the Chiltern integration appears to be going smoothly,” Barclays analysts said in a research note.",The company’s shares were up 3.4 percent at $171.79.,"LabCorp is also focusing on expanding partnerships. It has an ongoing collaboration with Walgreens Boots Alliance WBA.O, where it has patient service centers within Walgreens stores.","“We expect the partnership with Walgreens to expand both in number of stores and scope over the balance of 2018,” Chief Executive Officer David King said on a conference call with analysts.","Revenue from its diagnostics unit, which offers services such as genetic and pathology tests through labs throughout the United States, rose 8 percent to $1.64 billion in the quarter.","“In diagnostics, our focus on women’s health and medical drug monitoring as well as our strategic collaboration with 23andMe contributed to organic growth,” King said.","LabCorp provides its testing services to 23andMe, a Mountain View, California-based genetic testing company.",The diagnostics testing company raised its 2018 net revenue growth forecast to 10-12 percent from 9.5-11.5 percent. LabCorp reiterated its earnings forecast of $11.30 to $11.70 per share.,"Net earnings attributable to LabCorp was $173.2 million, or $1.67 per share, in the first quarter ended March 31, compared with $183 million, or $1.75 per share, a year earlier.","Excluding items, the company earned $2.78 per share. Analysts on average had estimated $2.63 per share, according to Thomson Reuters I/B/E/S.","Net revenue rose 18 percent to $2.85 billion, which also beat analysts’ estimates of $2.77 billion.","Last week, Quest Diagnostics DGX.N also reported a better-than-expected first quarter earnings, citing benefits of tax reform."
46,https://www.reuters.com/article/brief-labcorp-expects-partnership-with-w/brief-labcorp-expects-partnership-with-walgreens-to-expand-in-number-of-stores-and-scope-over-2018-idUSFWN1S214J,2018-04-25T16:15:45Z,BRIEF-LabCorp Expects Partnership With Walgreens To Expand In Number Of Stores And Scope Over 2018,April 25 (Reuters) - Laboratory Corporation of America Holdings:,* LABCORP CEO SAYS WE EXPECT PARTNERSHIP WITH WALGREENS BOOTS ALLIANCE TO EXPAND BOTH IN NUMBER OF STORES AND SCOPE OVER THE BALANCE OF 2018 - CONF CALL Further company coverage:
47,https://www.reuters.com/article/brief-labcorp-reports-q1-earnings-per-sh/brief-labcorp-reports-q1-earnings-per-share-1-67-idUSASC09X9D,2018-04-25T11:11:48Z,BRIEF-LabCorp Reports Q1 Earnings Per Share $1.67,April 25 (Reuters) - Laboratory Corporation of America Holdings:,* LABCORP ANNOUNCES STRONG 2018 FIRST QUARTER RESULTS AND UPDATES 2018 GUIDANCE,* Q1 REVENUE $2.85 BILLION VERSUS I/B/E/S VIEW $2.77 BILLION,* Q1 EARNINGS PER SHARE VIEW $2.63 -- THOMSON REUTERS I/B/E/S,* BOARD AUTHORIZED AN INCREASE IN COMPANY’S TOTAL SHARE REPURCHASE PROGRAM TO A TOTAL OF $1.0 BILLION,"* 2018 FREE CASH FLOW GUIDANCE OF $1.1 BILLION TO $1.2 BILLION, UNCHANGED FROM PRIOR GUIDANCE","* 2018 ADJUSTED EPS GUIDANCE OF $11.30 TO $11.70, UNCHANGED FROM PRIOR GUIDANCE",* 2018 ADJUSTED EPS GUIDANCE NOW INCLUDES PROJECTED NEGATIVE IMPACT FROM ASC 606 OF ABOUT $0.20 TO $0.30 PER SHARE FOR FULL YEAR 2018,"* EFFECTIVE JANUARY 1, 2018, COMPANY ADOPTED FASB-ISSUED CONVERGED STANDARD ON REVENUE RECOGNITION (ASC 606)",* SEES 2018 REVENUE GROWTH OF 10.0% TO 12.0% OVER 2017 REVENUE OF $10.31 BILLION,* BACKLOG AT END OF QUARTER WAS $9.17 BILLION FOR COVANCE DRUG DEVELOPMENT Source text for Eikon: Further company coverage:
48,https://www.reuters.com/article/laboratory-corp-results/labcorp-quarterly-profit-falls-5-4-pct-idUSL3N1S23VL,2018-04-25T11:09:37Z,LabCorp quarterly profit falls 5.4 pct,"April 25 (Reuters) - Diagnostics testing company Laboratory Corp of America Holdings reported a 5.4 percent fall in quarterly profit on Wednesday, hurt by higher expenses.","Net earnings attributable to LabCorp was $173.2 million, or $1.67 per share, in the first quarter ended March 31, compared with $183 million, or $1.75 per share, a year earlier.","However, net revenue rose 18 percent to $2.85 billion. (Reporting by Akankshita Mukhopadhyay in Bengaluru; Editing by Anil D’Silva)"
49,https://www.reuters.com/article/brief-labcorp-says-co-mount-sinai-health/brief-labcorp-says-co-mount-sinai-health-system-have-begun-implementing-program-across-mount-sinai-system-idUSFWN1S110W,2018-04-24T13:16:26Z,"BRIEF-Labcorp Says Co, Mount Sinai Health System Have Begun Implementing Program Across Mount Sinai System",April 24 (Reuters) - Laboratory Corporation of America Holdings:,"* LABCORP - CO, MOUNT SINAI HEALTH SYSTEM HAVE BEGUN IMPLEMENTING PROGRAM TO STANDARDIZE & OPTIMIZE INPATIENT LAB SERVICES ACROSS MOUNT SINAI SYSTEM","* LABCORP SAYS CO, MOUNT SINAI ENTERED INTO CONTRACT THAT WILL ""ENHANCE"" LAB OPERATIONS AT EACH OF MOUNT SINAI'S 7 ACUTE CARE HOSPITALS - SEC FILING Source text:(bit.ly/2qVixSp) Further company coverage:"
50,https://www.reuters.com/article/brief-labcorp-co-walgreens-announce-expa/brief-labcorp-co-walgreens-announce-expansion-of-their-labcorp-at-walgreens-collaboration-into-florida-idUSFWN1S00IT,2018-04-23T12:00:17Z,"BRIEF-Labcorp - Co, Walgreens Announce Expansion Of Their Labcorp At Walgreens Collaboration Into Florida",April 23 (Reuters) - Laboratory Corporation of America Holdings:,"* LABCORP - CO, WALGREENS ANNOUNCE EXPANSION OF THEIR LABCORP AT WALGREENS COLLABORATION INTO FLORIDA",* LABCORP - TEN NEW LABCORP PATIENT SERVICE CENTERS WILL OPEN WITHIN WALGREENS STORES IN APRIL & MAY Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)
